Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 8, 2003
- Alfresa Holdings: Fukujin, Azwell Show Mixed Results
December 8, 2003
- BULLETIN
December 8, 2003
- Astis: Consolidated Sales Down 2.1% at \43,756 Mil.
December 8, 2003
- Basic Policy on National Hospital Organization Issued
December 8, 2003
- Seiwa Sangyo: Consolidated Sales Rise 4.8% to \43.6 Bil.
December 8, 2003
- Nurse to Participate in Chuikyo as Expert Member
December 8, 2003
- Tsumura: Sales of Ethical Kampo Down 3.4%
December 8, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 8, 2003
- Zeria: Consumer Healthcare Brisk, but Ethical Sluggish
December 8, 2003
- Press Seminar
December 8, 2003
- SSP: Sales of OTC Products Down 4.8% to \23.8 Bil.
December 8, 2003
- Semi-annual Business Result
December 8, 2003
- Mutual GMP Recognition Discussed: MOSS Followup Talks
December 1, 2003
- PRESS SEMINAR
December 1, 2003
- Semi-annual Business Results
December 1, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 1, 2003
- Mochida: Profits Decline Despite Slight Growth in Pharma Sales
December 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 1, 2003
- Fuso: Profits Marked for 1st Time in 3 Years
December 1, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…